Viswanathan Ramasamy

Employment

• Sun Pharma Scientific Manager
  2021 - Present
• International Centre For Genetic Engineering and Biotechnology New Delhi Research Scientist
  2020 - Present

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (8)

• Antibody-Dependent Enhancement: A Challenge for Developing a Safe Dengue Vaccine
  Frontiers in Cellular and Infection Microbiology 2020 DOI: 10.3389/fcimb.2020.572681
  +Save
• Dengue and Zika virus infections are enhanced by live attenuated dengue vaccine but not by recombinant DSV4 vaccine candidate in mouse models
  EBioMedicine 2020 DOI: 10.1016/j.ebiom.2020.102991
  +Save
• Zika virus envelope nanoparticle antibodies protect mice without risk of disease enhancement
  EBioMedicine 2020 DOI: 10.1016/j.ebiom.2020.102738
  +Save
• Next generation designer virus-like particle vaccines for dengue
  Expert Review of Vaccines 2019 DOI: 10.1080/14760584.2019.1562909
  +Save
• Pichia pastoris-expressed Zika virus envelope domain III on a virus-like particle platform: Design, production and immunological evaluation
  Pathogens and Disease 2019 DOI: 10.1093/femspd/ftz026
  +Save
• A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice
  PLoS Neglected Tropical Diseases 2018 DOI: 10.1371/journal.pntd.0006191
  +Save
• Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies
  BMC Biotechnology 2016 DOI: 10.1186/s12896-016-0280-y
  +Save
• Dengue-specific subviral nanoparticles: Design, creation and characterization
  Journal of Nanobiotechnology 2013 DOI: 10.1186/1477-3155-11-15
  +Save